Ririno Honma1, Naoya Sakamoto1, Akira Ishikawa1, Daiki Taniyama1, Kaho Fukada1, Takuya Hattori1, Kazuhiro Sentani1, Naohide Oue1, Kazuaki Tanabe2, Hideki Ohdan2, Wataru Yasui3. 1. Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. 2. Department of Gastroenterological and Transplant Surgery, Applied Life Sciences, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan. 3. Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan wyasui@hiroshima-u.ac.jp.
Abstract
BACKGROUND/AIM: Gastric cancer (GC) is one of the most common malignancies worldwide. Gremlin1 is an antagonist of bone morphogenetic proteins that plays a critical role in several biological processes including cancer biology. MATERIALS AND METHODS: We immunohistochemically examined the expression and distribution of Gremlin1 in non-neoplastic gastric mucosa in a series of 159 GC cases. RESULTS: Among 159 GC primary tumors, 59 (37%) were positive for Gremlin1. Gremlin1-negative GC cases showed significantly more advanced clinicopathologic factors and a trend toward intestinal-type GC. Gremlin1 expression was also frequently observed in MUC5AC-positive and G-type GC cases. Gremlin1-negative GCs had a poorer survival rate than Gremlin1-positive GCs (p=0.002). Univariate and multivariate analyses revealed that Gremlin1 expression is an independent predictor of survival in GCs. CONCLUSION: These results indicate that Gremlin1 could be involved in GC progression and may be a good marker of long-term survival in GC. Copyright
BACKGROUND/AIM: Gastric cancer (GC) is one of the most common malignancies worldwide. Gremlin1 is an antagonist of bone morphogenetic proteins that plays a critical role in several biological processes including cancer biology. MATERIALS AND METHODS: We immunohistochemically examined the expression and distribution of Gremlin1 in non-neoplastic gastric mucosa in a series of 159 GC cases. RESULTS: Among 159 GC primary tumors, 59 (37%) were positive for Gremlin1. Gremlin1-negative GC cases showed significantly more advanced clinicopathologic factors and a trend toward intestinal-type GC. Gremlin1 expression was also frequently observed in MUC5AC-positive and G-type GC cases. Gremlin1-negative GCs had a poorer survival rate than Gremlin1-positive GCs (p=0.002). Univariate and multivariate analyses revealed that Gremlin1 expression is an independent predictor of survival in GCs. CONCLUSION: These results indicate that Gremlin1 could be involved in GC progression and may be a good marker of long-term survival in GC. Copyright